MedPath

imuflex wb-sp blood bag system with integral whole blood leukocyte reduction filter (saving platelets) with diversion blood sampling arm

IMUFLEX WB-SP BLOOD BAG SYSTEM with Integral Whole Blood Leukocyte Reduction Filter (Saving Platelets) with Diversion Blood Sampling Arm

Approved
Approval ID

4d08424e-1ae1-41a4-b50b-e4ce4b828bdd

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 10, 2021

Manufacturers
FDA

Terumo Corporation

DUNS: 690543319

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Anticoagulant Citrate Phosphate Dextrose (CPD)

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code53877-010
Application NumberBN880217
Product Classification
M
Marketing Category
C73594
G
Generic Name
Anticoagulant Citrate Phosphate Dextrose (CPD)
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateDecember 10, 2021
FDA Product Classification

INGREDIENTS (5)

Anhydrous Citric AcidActive
Quantity: 209 mg in 70 mL
Code: XF417D3PSL
Classification: ACTIB
WaterInactive
Code: 059QF0KO0R
Classification: IACT
Dextrose MonohydrateActive
Quantity: 1.79 g in 70 mL
Code: LX22YL083G
Classification: ACTIB
Sodium Phosphate, Monobasic, Unspecified FormActive
Quantity: 156 mg in 70 mL
Code: 3980JIH2SW
Classification: ACTIB
Trisodium Citrate DihydrateActive
Quantity: 1.84 g in 70 mL
Code: B22547B95K
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

imuflex wb-sp blood bag system with integral whole blood leukocyte reduction filter (saving platelets) with diversion blood sampling arm - FDA Drug Approval Details